Christian Razo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Razo has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
María J. Ríos-Blancas
Fundación Carlos Slim, Mexico City, Mexico
3 shared publicationsRafael Lozano
Departamento de Salud Pública, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico
3 shared publicationsAlejandra Montoya
Fundación "Carlos Slim" Mexico City Mexico
2 shared publicationsAleksandr Y. Aravkin
Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
2 shared publicationsAlison Bowman
University of Washington
2 shared publicationsCaroline Kinuthia
University of Washington
2 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e039204
Comparing 3 Evidence‐Based Strategies to Reduce Cardiovascular Disease Burden: An Individual‐Based Cardiometabolic Policy Simulation
Background: Understanding the real‐world impact of clinical trials that change risk factors is important for health policy. We developed a microsimulation that estimates the population‐level benefits in each US state of cardiometabolic interventions. Methods: We designed a state‐specific agent‐based simulation model with 51 million in silico individuals and estimated results for 2023 to 2040. Input data reflected current cardiometabolic health and the effects of interventions and risk factors. We constructed 3 health policy intervention scenarios based on randomized controlled trials proven to improve cardiometabolic population health: improved access to fixed‐dose combination antihypertensive medication, a pharmacist‐led intervention with phone‐based reminders to increase adherence to statin and antihypertensive medications at the time they are initiated, and a community‐based lifestyle and behavior intervention designed to prevent diabetes. Outcomes included CVD events, deaths, and disability‐adjusted life years (DALYs). Results: Our simulation included a representative population of the United States, accurate at the age, sex, and state level. By 2040, the fixed‐dose combination intervention was estimated to have prevented 776 000 (95% uncertainty interval, 578 000–956 000) CVD DALYs and 44 600 (95% uncertainty interval, 32 700–55 600) deaths annually. The pharmacist‐led intervention prevented 170 000 (95% uncertainty interval, 129 000–208 000) CVD DALYs, and the community‐based intervention prevented 152 000 (95% uncertainty interval, 128 000–173 000) CVD DALYs. Conclusions: A fixed‐dose combination of antihypertensives could prevent 1.2% of total CVD DALYs, with smaller benefits from adherence and lifestyle‐focused programs. Impact of interventions varied by state. Providing accurate population‐level estimates can help local health policy decision‐makers implement the most impactful interventions.
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e039204
Open AccessComparing 3 Evidence‐Based Strategies to Reduce Cardiovascular Disease Burden: An Individual‐Based Cardiometabolic Policy Simulation
Background: Understanding the real‐world impact of clinical trials that change risk factors is important for health policy. We developed a microsimulation that estimates the population‐level benefits in each US state of cardiometabolic interventions. Methods: We designed a state‐specific agent‐based simulation model with 51 million in silico individuals and estimated results for 2023 to 2040. Input data reflected current cardiometabolic health and the effects of interventions and risk factors. We constructed 3 health policy intervention scenarios based on randomized controlled trials proven to improve cardiometabolic population health: improved access to fixed‐dose combination antihypertensive medication, a pharmacist‐led intervention with phone‐based reminders to increase adherence to statin and antihypertensive medications at the time they are initiated, and a community‐based lifestyle and behavior intervention designed to prevent diabetes. Outcomes included CVD events, deaths, and disability‐adjusted life years (DALYs). Results: Our simulation included a representative population of the United States, accurate at the age, sex, and state level. By 2040, the fixed‐dose combination intervention was estimated to have prevented 776 000 (95% uncertainty interval, 578 000–956 000) CVD DALYs and 44 600 (95% uncertainty interval, 32 700–55 600) deaths annually. The pharmacist‐led intervention prevented 170 000 (95% uncertainty interval, 129 000–208 000) CVD DALYs, and the community‐based intervention prevented 152 000 (95% uncertainty interval, 128 000–173 000) CVD DALYs. Conclusions: A fixed‐dose combination of antihypertensives could prevent 1.2% of total CVD DALYs, with smaller benefits from adherence and lifestyle‐focused programs. Impact of interventions varied by state. Providing accurate population‐level estimates can help local health policy decision‐makers implement the most impactful interventions.
- Open Access
- 7 January 2025
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 160 (4) , 442-450
Registration of deaths in children under five years of age has improved in Mexico, however, the underreporting has not yet been eliminated
Background: The underreporting of vital statistics poses a problem for the quality of information. To address underreporting, Mexico implemented the “I...
- 7 January 2025
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 160 (4) , 442-450
Open AccessRegistration of deaths in children under five years of age has improved in Mexico, however, the underreporting has not yet been eliminated
Background: The underreporting of vital statistics poses a problem for the quality of information. To address underreporting, Mexico implemented the “I...
- Open Access
Comparing Three Evidence-Based Strategies to Reduce Cardiovascular Disease Burden: An Individual-Based Cardiometabolic Policy Simulation
• Background: Understanding the real-world impact of clinical trials is important for informing health care policy. This is particularly true when trials are designed to show changes in surrogate endpoints such as changes in risk factors rather than events or mortality. We developed an agent-based microsimulation that estimates the population-level benefits in each US state for cardiometabolic health interventions shown to improve risk factors. • Methods: We designed a large-scale, location-specific agent-based simulation model with a population of 51 million in silico individuals and estimated results for the years 2023 to 2040 in 30-day steps for each of the 50 states and District of Columbia. Input data reflected current cardiometabolic health in each state and the effects of interventions and risk factors on outcomes. We constructed three health policy intervention scenarios based on successful randomized controlled trials designed to improve cardiometabolic population health: improved access to fixed-dose combination (FDC) antihypertensive medication, a pharmacist-led intervention to increase adherence to statin and antihypertensives medications at the time they are initiated (Pharmacy), and a community-based lifestyle and behavior intervention designed to prevent diabetes (Community). Outcomes included myocardial infarction, ischemic and non-ischemic heart failure, and ischemic stroke events, deaths, and disability-adjusted life years (DALYs). • Results: Our simulation included a representative population of the United States, accurate at the age, sex, and state level, with individual people simulated over 17 years. By the year 2040, the FDC intervention was estimated to have prevented 776,000 (95% UI 578,000– 956,000) CVD DALYs and 44,600 (95% UI 32,700–55,600) deaths annually. Reductions in ischemic heart disease deaths accounted for 76.5% of the total reductions in CVD deaths. The Pharmacist intervention prevented 170,000 (95% UI 129,000–208,000) CVD DALYs, and the Community intervention prevented 152,000 (95% UI 128,000–173,000) CVD DALYs. • Conclusions: A fixed-dose combination of antihypertensives could prevent 1.2% of total CVD DALYs, with smaller benefits from adherence and lifestyle-focused programs and impact of interventions varying by state. The greatest reduction was in incident myocardial infarctions and ischemic heart disease deaths. Providing accurate population-level estimates at the state level can help local health policy decision-makers implement the most impactful interventions. Clinical Perspective: What is new? Using person-level simulation, we have translated randomized trial results showing improvements in blood pressure, BMI, fasting plasma glucose, and LDL-C, and adherence to medication into real-world impact including forecasting cardiovascular disease events and deaths for the United States through the year 2040. A national, agent-based microsimulation for all 50 US states and DC allows us to assess how risk factor interventions will differentially affect demographic groups and locations. What are the clinical implications? Broad adoption of fixed-dose combination medication for hypertension had the largest health benefit in all states. Interventions to improve adherence to medications or promote behavior change led to smaller reductions in disease burden. Direct comparison of the estimated real-world impact of clinical and community-based interventions can guide ongoing efforts to reduce the population burden of cardiovascular disease and resulting disparities.
Open AccessComparing Three Evidence-Based Strategies to Reduce Cardiovascular Disease Burden: An Individual-Based Cardiometabolic Policy Simulation
• Background: Understanding the real-world impact of clinical trials is important for informing health care policy. This is particularly true when trials are designed to show changes in surrogate endpoints such as changes in risk factors rather than events or mortality. We developed an agent-based microsimulation that estimates the population-level benefits in each US state for cardiometabolic health interventions shown to improve risk factors. • Methods: We designed a large-scale, location-specific agent-based simulation model with a population of 51 million in silico individuals and estimated results for the years 2023 to 2040 in 30-day steps for each of the 50 states and District of Columbia. Input data reflected current cardiometabolic health in each state and the effects of interventions and risk factors on outcomes. We constructed three health policy intervention scenarios based on successful randomized controlled trials designed to improve cardiometabolic population health: improved access to fixed-dose combination (FDC) antihypertensive medication, a pharmacist-led intervention to increase adherence to statin and antihypertensives medications at the time they are initiated (Pharmacy), and a community-based lifestyle and behavior intervention designed to prevent diabetes (Community). Outcomes included myocardial infarction, ischemic and non-ischemic heart failure, and ischemic stroke events, deaths, and disability-adjusted life years (DALYs). • Results: Our simulation included a representative population of the United States, accurate at the age, sex, and state level, with individual people simulated over 17 years. By the year 2040, the FDC intervention was estimated to have prevented 776,000 (95% UI 578,000– 956,000) CVD DALYs and 44,600 (95% UI 32,700–55,600) deaths annually. Reductions in ischemic heart disease deaths accounted for 76.5% of the total reductions in CVD deaths. The Pharmacist intervention prevented 170,000 (95% UI 129,000–208,000) CVD DALYs, and the Community intervention prevented 152,000 (95% UI 128,000–173,000) CVD DALYs. • Conclusions: A fixed-dose combination of antihypertensives could prevent 1.2% of total CVD DALYs, with smaller benefits from adherence and lifestyle-focused programs and impact of interventions varying by state. The greatest reduction was in incident myocardial infarctions and ischemic heart disease deaths. Providing accurate population-level estimates at the state level can help local health policy decision-makers implement the most impactful interventions. Clinical Perspective: What is new? Using person-level simulation, we have translated randomized trial results showing improvements in blood pressure, BMI, fasting plasma glucose, and LDL-C, and adherence to medication into real-world impact including forecasting cardiovascular disease events and deaths for the United States through the year 2040. A national, agent-based microsimulation for all 50 US states and DC allows us to assess how risk factor interventions will differentially affect demographic groups and locations. What are the clinical implications? Broad adoption of fixed-dose combination medication for hypertension had the largest health benefit in all states. Interventions to improve adherence to medications or promote behavior change led to smaller reductions in disease burden. Direct comparison of the estimated real-world impact of clinical and community-based interventions can guide ongoing efforts to reduce the population burden of cardiovascular disease and resulting disparities.
- Open Access
- 22 February 2024
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 159 (6) , 469-478
The burden of disease, injuries, and risk factors in Mexico: 1990-2021 update
Background: For thirty years, Mexico has studied the burden of disease in order to inform health decisions. Objective: To analyze the burden of disease, inju...
- 22 February 2024
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 159 (6) , 469-478
Open AccessThe burden of disease, injuries, and risk factors in Mexico: 1990-2021 update
Background: For thirty years, Mexico has studied the burden of disease in order to inform health decisions. Objective: To analyze the burden of disease, inju...
- 19 December 2023
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 159 (6) , 469-478
La carga de la enfermedad, lesiones y factores de riesgo en México. Actualización del período 1990-2021
Antecedentes: Desde hace treinta años, México ha estudiado la carga de la enfermedad para sustentar decisiones en salud. Objetivo: Analizar la carga de enfermedad, lesiones y factores de riesgo en México entre 1990 y 2021. Material y métodos: Se utilizaron las estimaciones del Global Burden of Disease 2021 para analizar la mortalidad, los años de vida perdidos por muerte prematura, los años vividos con discapacidad y los años de vida saludable perdidos, así como la carga atribuible a los factores de riesgos por sexo, edad y entidad federativa. Resultados: La mortalidad infantil disminuyó 39.4 % de 1990 a 2000, y 49.0 % de 2000 a 2019. En el ámbito nacional, la mortalidad decreció 27.5 % entre 1990 y 2019, pero ascendió en 2020 y 2021 en todos los estados, especialmente en adultos de 35 a 64 años, debido a la pandemia de COVID-19, que contribuyó con 24.3 % de las defunciones en 2019. Se observaron diferencias significativas en la mortalidad según la edad y el sexo. La carga atribuible a los factores de riesgo metabólicos se incrementó, mientras que la atribuible el consumo de alcohol y tabaco disminuyó. El acceso al agua potable y saneamiento mejoró. Conclusiones: Evaluar la carga de enfermedad es crucial para diseñar estrategias eficaces para abordar las necesidades actuales y los futuros desafíos en salud.
- 19 December 2023
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 159 (6) , 469-478
La carga de la enfermedad, lesiones y factores de riesgo en México. Actualización del período 1990-2021
Antecedentes: Desde hace treinta años, México ha estudiado la carga de la enfermedad para sustentar decisiones en salud. Objetivo: Analizar la carga de enfermedad, lesiones y factores de riesgo en México entre 1990 y 2021. Material y métodos: Se utilizaron las estimaciones del Global Burden of Disease 2021 para analizar la mortalidad, los años de vida perdidos por muerte prematura, los años vividos con discapacidad y los años de vida saludable perdidos, así como la carga atribuible a los factores de riesgos por sexo, edad y entidad federativa. Resultados: La mortalidad infantil disminuyó 39.4 % de 1990 a 2000, y 49.0 % de 2000 a 2019. En el ámbito nacional, la mortalidad decreció 27.5 % entre 1990 y 2019, pero ascendió en 2020 y 2021 en todos los estados, especialmente en adultos de 35 a 64 años, debido a la pandemia de COVID-19, que contribuyó con 24.3 % de las defunciones en 2019. Se observaron diferencias significativas en la mortalidad según la edad y el sexo. La carga atribuible a los factores de riesgo metabólicos se incrementó, mientras que la atribuible el consumo de alcohol y tabaco disminuyó. El acceso al agua potable y saneamiento mejoró. Conclusiones: Evaluar la carga de enfermedad es crucial para diseñar estrategias eficaces para abordar las necesidades actuales y los futuros desafíos en salud.
- Top Cited PapersOpen Access
- 10 October 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (10) , 2038-2044
The Burden of Proof studies: assessing the evidence of risk
Exposure to risks throughout life results in a wide variety of outcomes. Objectively judging the relative impact of these risks on personal and population health is fundamental to individual survival and societal prosperity. Existing mechanisms to quantify and rank the magnitude of these myriad effects and the uncertainty in their estimation are largely subjective, leaving room for interpretation that can fuel academic controversy and add to confusion when communicating risk. We present a new suite of meta-analyses—termed the Burden of Proof studies—designed specifically to help evaluate these methodological issues objectively and quantitatively. Through this data-driven approach that complements existing systems, including GRADE and Cochrane Reviews, we aim to aggregate evidence across multiple studies and enable a quantitative comparison of risk–outcome pairs. We introduce the burden of proof risk function (BPRF), which estimates the level of risk closest to the null hypothesis that is consistent with available data. Here we illustrate the BPRF methodology for the evaluation of four exemplar risk–outcome pairs: smoking and lung cancer, systolic blood pressure and ischemic heart disease, vegetable consumption and ischemic heart disease, and unprocessed red meat consumption and ischemic heart disease. The strength of evidence for each relationship is assessed by computing and summarizing the BPRF, and then translating the summary to a simple star rating. The Burden of Proof methodology provides a consistent way to understand, evaluate and summarize evidence of risk across different risk–outcome pairs, and informs risk analysis conducted as part of the Global Burden of Diseases, Injuries, and Risk Factors Study.
- 10 October 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (10) , 2038-2044
Top Cited PapersOpen AccessThe Burden of Proof studies: assessing the evidence of risk
Exposure to risks throughout life results in a wide variety of outcomes. Objectively judging the relative impact of these risks on personal and population health is fundamental to individual survival and societal prosperity. Existing mechanisms to quantify and rank the magnitude of these myriad effects and the uncertainty in their estimation are largely subjective, leaving room for interpretation that can fuel academic controversy and add to confusion when communicating risk. We present a new suite of meta-analyses—termed the Burden of Proof studies—designed specifically to help evaluate these methodological issues objectively and quantitatively. Through this data-driven approach that complements existing systems, including GRADE and Cochrane Reviews, we aim to aggregate evidence across multiple studies and enable a quantitative comparison of risk–outcome pairs. We introduce the burden of proof risk function (BPRF), which estimates the level of risk closest to the null hypothesis that is consistent with available data. Here we illustrate the BPRF methodology for the evaluation of four exemplar risk–outcome pairs: smoking and lung cancer, systolic blood pressure and ischemic heart disease, vegetable consumption and ischemic heart disease, and unprocessed red meat consumption and ischemic heart disease. The strength of evidence for each relationship is assessed by computing and summarizing the BPRF, and then translating the summary to a simple star rating. The Burden of Proof methodology provides a consistent way to understand, evaluate and summarize evidence of risk across different risk–outcome pairs, and informs risk analysis conducted as part of the Global Burden of Diseases, Injuries, and Risk Factors Study.
- Top Cited PapersOpen Access
- 10 October 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (10) , 2056-2065
Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study
High systolic blood pressure (SBP) is a major risk factor for ischemic heart disease (IHD), the leading cause of death worldwide. Using data from published observational studies and controlled trials, we estimated the mean SBP–IHD dose–response function and burden of proof risk function (BPRF), and we calculated a risk outcome score (ROS) and corresponding star rating (one to five). We found a very strong, significant harmful effect of SBP on IHD, with a mean risk—relative to that at 100 mm Hg SBP—of 1.39 (95% uncertainty interval including between-study heterogeneity 1.34–1.44) at 120 mm Hg, 1.81 (1.70–1.93) at 130 mm Hg and 4.48 (3.81–5.26) at 165 mm Hg. The conservative BPRF measure indicated that SBP exposure between 107.5 and 165.0 mm Hg raised risk by 101.36% on average, yielding a ROS of 0.70 and star rating of five. Our analysis shows that IHD risk was already increasing at 120 mm Hg SBP, rising steadily up to 165 mm Hg and increasing less steeply above that point. Our study endorses the need to prioritize and strengthen strategies for screening, to raise awareness of the need for timely diagnosis and treatment of hypertension and to increase the resources allocated for understanding primordial prevention of elevated blood pressure.
- 10 October 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (10) , 2056-2065
Top Cited PapersOpen AccessEffects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study
High systolic blood pressure (SBP) is a major risk factor for ischemic heart disease (IHD), the leading cause of death worldwide. Using data from published observational studies and controlled trials, we estimated the mean SBP–IHD dose–response function and burden of proof risk function (BPRF), and we calculated a risk outcome score (ROS) and corresponding star rating (one to five). We found a very strong, significant harmful effect of SBP on IHD, with a mean risk—relative to that at 100 mm Hg SBP—of 1.39 (95% uncertainty interval including between-study heterogeneity 1.34–1.44) at 120 mm Hg, 1.81 (1.70–1.93) at 130 mm Hg and 4.48 (3.81–5.26) at 165 mm Hg. The conservative BPRF measure indicated that SBP exposure between 107.5 and 165.0 mm Hg raised risk by 101.36% on average, yielding a ROS of 0.70 and star rating of five. Our analysis shows that IHD risk was already increasing at 120 mm Hg SBP, rising steadily up to 165 mm Hg and increasing less steeply above that point. Our study endorses the need to prioritize and strengthen strategies for screening, to raise awareness of the need for timely diagnosis and treatment of hypertension and to increase the resources allocated for understanding primordial prevention of elevated blood pressure.
- Open Access
- 29 October 2020
- Published by BMJ in BMJ Global Health
- Vol. 5 (10) , e002382
Advances and challenges on the path toward the SDGs: subnational inequalities in Mexico, 1990–2017
Background: The sustainable development goals (SDGs) have generated momentum for global health, aligning efforts from governments and international organisations toward a set of goals that are expected to reflect improvements in life conditions across the globe. Mexico has huge social inequalities that can affect access to quality care and health outcomes. The objective of this study is to analyse inequalities among Mexico’s 32 states on the health-related SDG indicators (HRSDGIs) from 1990 to 2017. Methods: These analyses rely on the estimation of HRSDGIs as part of the Global Burden of Disease study 2017. We estimated the concentration index for 40+3 HRSDGI stratified by Socio-demographic Index and marginalisation index, and then for indicators where inequalities were identified, we ran decomposition analyses using structural variables such as gross domestic product per capita, poverty and health expenditure. Findings: Mexico has made progress on most HRSDGIs, but current trends in improvement do not appear to fast enough to meet 2030 targets. Out of 43 HRSDGIs, we identified evidence of inequality between Mexico’s states for 30 indicators; of those, 23 HRSDGIs were unequal distributed affecting states with lower development and seven affecting states with higher development. The decomposition analysis indicates that social determinants of health are major drivers of HRSDGI inequalities in Mexico. Interpretation: Modifying current trends for HRSDGIs will require subnational-level and national-level policy action, of which should be informed by the latest available data and monitoring on the health-related SDGs. The SDGs’ overarching objective of leaving no-one behind should be prioritised not only for individuals but also for communities and other subnational levels.
- 29 October 2020
- Published by BMJ in BMJ Global Health
- Vol. 5 (10) , e002382
Open AccessAdvances and challenges on the path toward the SDGs: subnational inequalities in Mexico, 1990–2017
Background: The sustainable development goals (SDGs) have generated momentum for global health, aligning efforts from governments and international organisations toward a set of goals that are expected to reflect improvements in life conditions across the globe. Mexico has huge social inequalities that can affect access to quality care and health outcomes. The objective of this study is to analyse inequalities among Mexico’s 32 states on the health-related SDG indicators (HRSDGIs) from 1990 to 2017. Methods: These analyses rely on the estimation of HRSDGIs as part of the Global Burden of Disease study 2017. We estimated the concentration index for 40+3 HRSDGI stratified by Socio-demographic Index and marginalisation index, and then for indicators where inequalities were identified, we ran decomposition analyses using structural variables such as gross domestic product per capita, poverty and health expenditure. Findings: Mexico has made progress on most HRSDGIs, but current trends in improvement do not appear to fast enough to meet 2030 targets. Out of 43 HRSDGIs, we identified evidence of inequality between Mexico’s states for 30 indicators; of those, 23 HRSDGIs were unequal distributed affecting states with lower development and seven affecting states with higher development. The decomposition analysis indicates that social determinants of health are major drivers of HRSDGI inequalities in Mexico. Interpretation: Modifying current trends for HRSDGIs will require subnational-level and national-level policy action, of which should be informed by the latest available data and monitoring on the health-related SDGs. The SDGs’ overarching objective of leaving no-one behind should be prioritised not only for individuals but also for communities and other subnational levels.